drugset / Trial / NCT00002372

A Study of 141W94 in Combination With Other Anti-HIV Drugs

NCT00002372 ↗

Phase 1 Completed 48 enrolled Glaxo Wellcome
Open-labelTreatment

Summary

To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing. To determine the steady-state pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after multiple oral dosing. To assess the safety and tolerability of multiple doses of 141W94 when combined with saquinavir, indinavir and nelfinavir.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Amprenavir Other / unclassified — Oral
Subject Amprenavir Other / unclassified — —
Subject INDINAVIR ANHYDROUS Other / unclassified — Oral
Subject Nelfinavir Other / unclassified — Oral
Subject Saquinavir Small molecule — Oral